Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 3,459 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Matching Oral Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 17, 2026, 6:06 PM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period

NCT05175105
View directory record Official record
Conditions
Pediatric Pyruvate Kinase Deficiency, Pediatric Hemolytic Anemia
Interventions
Mitapivat, Mitapivat-matching placebo
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
11
States / cities
Palo Alto, California • Aurora, Colorado • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

NCT02054156
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
azithromycin, placebo, Tobramycin solution for inhalation
Drug
Lead sponsor
Bonnie Ramsey
Other
Eligibility
6 Months to 18 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
45
States / cities
Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 17, 2026, 6:06 PM EDT
Active, not recruiting Phase 2 Interventional

Efficacy and Safety of Gemlapodect (NOE-105) in Adults and Adolescents With Tourette Syndrome

NCT06315751
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Gemlapodect, Placebo
Drug
Lead sponsor
Noema Pharma AG
Industry
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
31
States / cities
Sun City, Arizona • Bellflower, California • Glendale, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Driving Simulation to Assess Non-Sedative Effects of Tolperisone

NCT03353922
View directory record Official record
Conditions
Driving Impaired
Interventions
Cyclobenzaprine 10 Mg Oral Tablet, Placebo Oral Tablet
Drug
Lead sponsor
Neurana Pharmaceuticals, Inc.
Industry
Eligibility
21 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Long Beach, California • Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 1, 2022 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Interaction Study of Clopidogrel 300/75 mg Given Alone or Concomitantly With Omeprazole 80 mg in Healthy Subjects

NCT01129375
View directory record Official record
Conditions
Healthy
Interventions
clopidogrel, placebo, omeprazole
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 15, 2011 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

NCT00833703
View directory record Official record
Conditions
Heart Defects, Congenital
Interventions
Clopidogrel, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Months and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 22, 2011 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 4 Interventional Results available

Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor

NCT04392375
View directory record Official record
Conditions
Preeclampsia Severe
Interventions
Nifedipine 30 MG, Placebos
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 4 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained-Release (DVS SR) in Adult Outpatients With Major Depressive Disorder (MDD)

NCT01432457
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
desvenlafaxine succinate sustained-release 50 mg/day, desvenlafaxine succinate sustained-release 100 mg/day, placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
61
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Arcadia, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2014 · Synced Oct 17, 2026, 6:06 PM EDT
Not yet recruiting Phase 2 Interventional

Role of Omega-DEK in Childhood Apraxia of Speech

NCT07216001
View directory record Official record
Conditions
Childhood Apraxia of Speech, Verbal Apraxia, Autism
Interventions
Omega-DEK, L-carnitine, Placebo
Drug
Lead sponsor
Claudia R. Morris
Other
Eligibility
36 Months to 6 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

Effectiveness of Sitagliptin for HIV Insulin Resistance and Inflammation

NCT01552694
View directory record Official record
Conditions
Inflammation, Macrophage Infiltration, Cardiovascular Disease
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 17, 2026, 6:06 PM EDT
Terminated Phase 2 Interventional Results available

Efficacy, Safety, Tolerability and Pharmacokinetics (PK) of Nilotinib (AMN107) in Pulmonary Arterial Hypertension (PAH)

NCT01179737
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Nilotinib, Placebo to nilotinib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Boston, Massachusetts • Ann Arbor, Michigan • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated May 1, 2014 · Synced Oct 17, 2026, 6:06 PM EDT
Withdrawn Phase 2 Interventional

Oral Nitrite Trial for Hypertension and Metabolic Syndrome

NCT02517697
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension
Interventions
14 Nitrogen (N) Sodium Nitrite, Placebo
Drug
Lead sponsor
Gladwin, Mark, MD
Individual
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2021 · Synced Oct 17, 2026, 6:06 PM EDT
Recruiting Phase 2 Interventional

LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

NCT05798923
View directory record Official record
Conditions
Pulmonary Hypertension Due to Lung Diseases and Hypoxia
Interventions
Placebo, LAM-001
Drug
Lead sponsor
IRulya Therapeutics Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
4
States / cities
Tucson, Arizona • New Haven, Connecticut • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
Interventions
Emricasan (5 mg), Emricasan (50 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
83
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating Nelotanserin for Treatment of REM Sleep Behavior Disorder in Subjects With Dementia (DLB or PDD)

NCT02708186
View directory record Official record
Conditions
Dementia With Lewy Bodies, REM Sleep Behavior Disorder, Parkinson's Disease Dementia
Interventions
Nelotanserin, Placebo
Drug
Lead sponsor
Axovant Sciences Ltd.
Industry
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 20 more
Source: ClinicalTrials.gov public record
Updated May 20, 2020 · Synced Oct 17, 2026, 6:06 PM EDT
Terminated Phase 3 Interventional

Efficacy of Ramelteon in Adults With Chronic Insomnia

NCT00672724
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,081 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effects of JNJ-42165279 on the Neural Basis of Anxiety Disorders in Healthy Male Volunteers

NCT01826786
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42165279 (100 mg), Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 4 Interventional

Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses

NCT04276259
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
Buprenorphine, Naltrexone, Oral Placebo, IM Placebo, Theta burst stimulation (TBS) of the ventromedial prefrontal cortex.
Drug · Device
Lead sponsor
Marta Peciña, MD PhD
Other
Eligibility
18 Years to 55 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 QT Study in Healthy Male Subjects

NCT01986894
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Volunteer Study
Interventions
Placebo, Pomalidomide, Moxifloxacin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 17, 2026, 6:06 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment

NCT01688882
View directory record Official record
Conditions
Bullous Pemphigoid
Interventions
QGE031, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
2
States / cities
Iowa City, Iowa • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

A Safety and Efficacy Study of Eltrombopag in Subjects With AML

NCT01890746
View directory record Official record
Conditions
Acute Leukaemia
Interventions
Daunorubicin, Cytarabine, Eltrombopag, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
14
States / cities
Farmington, Connecticut • Miami, Florida • Orlando, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional

An Inpatient Study of ALLN-346 (Engineered Urate Oxidase) in Hyperuricemic Subjects (Study 201)

NCT04987242
View directory record Official record
Conditions
Hyperuricemia, Gout, Chronic Kidney Diseases
Interventions
ALLN-346, Placebo
Drug
Lead sponsor
Allena Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 17, 2026, 6:06 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Trial of Suvorexant for Sleep in Children With Autism

NCT05546554
View directory record Official record
Conditions
Autism, Autism Spectrum Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
13 Years to 17 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 17, 2026, 6:06 PM EDT